The Motley Fool··Adria CiminoPfizer at a Crossroads: Patent Cliffs and Pipeline Bets Define Next Chapter
Pfizer faces patent cliffs and COVID vaccine decline, betting on oncology and obesity drug pipelines to drive future growth amid acquisition integration challenges.
PFELLYNVOclinical trialsacquisitions